Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care

Weranja K.B. Ranasinghe, Chad A. Reichard, Brian F. Chapin

Research output: Contribution to journalEditorialOtherpeer-review

1 Citation (Scopus)


Retrospective studies in selected patients have demonstrated a survival benefit with prostatectomy or radiotherapy (RT) of the primary tumor in metastatic hormone-sensitive prostate cancer (mHSPC). However, there is currently not enough evidence to recommend RT to the primary tumor as the standard of care for patients treated with androgen deprivation therapy plus abiraterone or docetaxel for low-volume mHSPC.

Original languageEnglish
Pages (from-to)543-545
Number of pages3
JournalEuropean Urology
Issue number5
Publication statusPublished - Nov 2019
Externally publishedYes

Cite this